Last reviewed · How we verify
Xaluprine
At a glance
| Generic name | Xaluprine |
|---|---|
| Sponsor | Kjeld Schmiegelow |
| Target | Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia
- Acute promyelocytic leukemia, FAB M3
Common side effects
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (PHASE2, PHASE3)
- Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid (PHASE4)
- Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |